Kristen Kennedy is an associate in the firm’s Business Law department and a member of its Life Sciences group. Kristen represents clients across the life sciences and technology industries in a wide variety of corporate and transactional matters, with a focus on public and private capital markets transactions, including initial public offerings, follow-on offerings, ATMs, and private placements. She also counsels clients on a wide array of corporate matters, including SEC reporting, securities law compliance, and corporate governance.
Experience
Kristen’s client representations include the following:
- Metagenomi in its $93.75 million initial public offering
- Olink in its $80.75 million follow-on offering
- Korro Bio in its business combination with Frequency Therapeutics, including a $117 million pre-closing private placement
- The underwriters of Taysha Gene Therapies in its $75 million follow-on offering
- The underwriters of J.Jill in its $71 million follow-on offering
- Barinthus Biotherapeutics (formerly Vaccitech) in its $110.5 million initial public offering
- The underwriters of NAPCO Security Technologies in its $74 million follow-on offering
- Rocket Pharmaceuticals in its $115 million follow-on offering
- Alkermes in the spinoff of its oncology business into Mural Oncology as a separate public company
- The underwriters of 1stDibs in its $132 million initial public offering
Professional Experience
Kristen served as the Editor-in-Chief of the Journal of Law and Policy during law school. She previously worked as a research specialist for Akin Gump Strauss Hauer & Feld LLP and as an archivist for the American Civil Liberties Union, and previously served as a Peace Corps volunteer in Kyrgyzstan.
Credentials
Education
JD2019
Brooklyn Law School
(cum laude)
BA
New York University
MLS
Queens College
Admissions
Bars
- New York
Publications
Author, “Copyright Infringement in Sound Recording: How Courts and Legislatures Can Get in Vogue in a Post-Ciccone World,” 25 J. L. & Pol'y 725, 2017